Arbutus Biopharma (LTS:0SGC) Beta: 0.7234 (As of Jun. 25, 2026)


LTS:0SGC Arbutus Biopharma Corp LTS:0SGC
53 GF Score
Price $3.32
GF Value $38.26
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Beta?

Arbutus Biopharma LTS:0SGC 53 Beta is 0.7234 as of Jun. 25, 2026. GuruFocus rates LTS:0SGC with a GF Score™ of 53/100 and a GF Value™ of $38.26. The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Arbutus Biopharma's Beta is 0.7234.


Arbutus Biopharma  (LTS:0SGC) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Arbutus Biopharma Beta Related Terms


Arbutus Biopharma Beta Historical Data

* Premium members only.

The historical data trend for Arbutus Biopharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma Beta Chart

Arbutus Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.31 0.55

Arbutus Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.59 0.41 0.55 0.51

LTS:0SGC vs SPRY, KURA, JANX: Beta Comparison

For the Biotechnology subindustry, Arbutus Biopharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Beta distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Beta falls into.


LTS:0SGC
53GF Score
Arbutus Biopharma Corp LTS:0SGC
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arbutus Biopharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.7234 mean?
Arbutus Biopharma (LTS:0SGC) has a Beta of 0.7234 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Arbutus Biopharma and its competitors.
Is Arbutus Biopharma's Beta too high?
Arbutus Biopharma's current Beta is 0.7234. Overall, Arbutus Biopharma has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Beta compare to SPRY and KURA?
Arbutus Biopharma's Beta of 0.7234 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Arbutus Biopharma and its competitors. Arbutus Biopharma's current Beta is 0.7234. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Arbutus Biopharma (LTS:0SGC) has a current Beta of 0.7234. The stock's GF Value™ is $38.26, compared to a current price of $3.32 — trading 91.3% below its estimated fair value. The current Beta is 0.7234. Arbutus Biopharma's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Arbutus Biopharma (LTS:0SGC), the current Beta is 0.7234 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (LTS:0SGC) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $3.32 is trading 91.3% below its estimated GF Value™ of $38.26.

Key valuation signals for LTS:0SGC:

  • Beta: 0.7234
  • GF Value™: $38.26 vs. price of $3.32 (91.3% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the LTS:0SGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arbutus Biopharma Business Description

Other Exchanges ABUS:USAI9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score

Get the complete analysis for LTS:0SGC

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.32
Price
$38.26
GF Value